The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 120.40
Bid: 120.00
Ask: 120.40
Change: -1.60 (-1.31%)
Spread: 0.40 (0.333%)
Open: 120.20
High: 121.60
Low: 120.20
Prev. Close: 122.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

Thu, 01st Apr 2021 12:00

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

4D Pharma PLC - Leeds-based live biotherapeutic products developer - Posts pretax loss of GBP30.3 million in 2020, widening from GBP29.0 million a year prior. Revenue more-than-doubles to GBP534,000 from GBP211,000. Administrative expenses double to GBP9.1 million from GBP4.4 million. "4D has made significant progress leading the field in the development of live biotherapeutics, and made great strides from a corporate perspective. In addition to the data we have generated in the field of oncology, we completed our merger with Longevity and obtained a NASDAQ listing which, together with a concurrent fundraise, provides 4D with approximately USD40 million of additional capital and a solid financial footing moving forward. This puts 4D pharma in a strong position to capitalise on multiple data readouts from our ongoing trials in asthma and oncology as well as facilitating the move into the clinic with our Parkinson's disease programme," says 4D Pharma.

----------

Sportech PLC - Edinburgh-based gambling technology firm - Posts pretax loss from continuing operations for 2020 of GBP10.6 million, widening 9.3% from GBP9.7 million a year prior. Revenue sinks to GBP20.0 million from GBP33.6 million. "Providing a long-term projection with any degree of certainty in this environment is challenging and unrealistic, however having negotiated several corporate transactions during the last 12 months, when completed, the group will have reduced investors' risk and simplified the structure and the opportunities ahead," says Sportech.

----------

BSF Enterprise PLC - UK-based company formed to undertake an acquisition - Posts pretax loss of GBP93,845 in the year ended September 30, 2020, narrowed from GBP94,398 a year prior. "In the context of this challenging capital raising environment during this Covid-19 pandemic, I believe that BSF represents an extremely attractive proposition to prospective acquisition counterparties considering listing on the London Stock Exchange and I remain confident that we will be able to execute an acquisition that creates value for our shareholders," says BSF.

----------

Nippon Active Value Fund PLC - Japan-focused investment firm - Posts net asset value per share at December 30 of 113.58 pence, in its annual report for the period from incorporation on October 22, 2019 to December 30, 2020. NAV per share increases 14% since IPO. Declares inaugural dividend of 0.85p per share. Says it will not target a dividend for future years but will substantially pay out distributable income for any particular period by way of dividend.

----------

Syncona Ltd - investor in life science companies - Notes results of portfolio company and biotechnology firm Freeline Therapeutics Holdings PLC. Freeline posts pretax loss for 2020 of USD96.2 million, widening from USD53.8 million a year prior. Research & development costs increase to USD76.1 million from USD47.0 million. "We are pleased with our current progress and aim to have three Freeline programs in the clinic by the end of 2021," said Theresa Heggie, Chief Executive Officer of Freeline.

----------

Horizonte Minerals PLC - nickel company focused on Brazil - Posts pretax loss of GBP2.6 million in 2020, widening 13% from GBP2.3 million a year prior. Administrative expenses increase to GBP2.9 million from GBP2.6 million. Says assets are not generating revenues. Does not declare any dividend in 2020, unchanged from a year prior. "The Covid-19 pandemic was unfortunately not an isolated event in 2020, it has continued in to 2021 and we will continue to feel its effects well into the medium term. However, with the accelerating rollout of a number of vaccines we are hopeful for a more certain, less interrupted year in 2021," says Horizonte.

----------

Proteome Sciences PLC - drug development services provider - Posts pretax profit of GBP245,000 in 2020, swinging from a loss of GBP36,000 a year before. Revenue increases to GBP4.8 million from GBP4.7 million. Administrative expenses fall 25% to GBP2.0 million from GBP2.7 million. "We have started an internal analysis on growing our business further in addition to our current activities. We believe that with our specialist expertise the market for our niche services has the potential to grow substantially as proteomics plays an increasingly vital role in drug discovery, development and in the response to current and future medical challenges," says Proteome.

----------

Arbuthnot Banking Group PLC - London-based private and commercial banking - Says subsidiary Arbuthnot Latham completes acquisition of provider of vehicle finance Asset Alliance Group Holdings Ltd. Says the consideration is now anticipated to be approximately GBP10.1 million.

----------

Stanley Gibbons Group PLC - London-based collectible postage stamp retailer - Says it has seen increased levels of digital activity and remote selling of albums and accessories contrasting with lower levels of high ticket sales and in person activities as a result of the third lockdown throughout the year to March 31. Says second half trading was better than the first. "We are hopeful that a vaccine led relaxing of restrictions is not only permanent but encourages activity levels to return at pace, however, this is hard to predict and we have plans in place if this is not how things develop," says Stanley Gibbons.

----------

Great Western Mining Corp PLC - mineral exploration and development company with gold, silver and copper assets in the US - Says drilling has start in Nevada to test a prospective copper target and is likely to be followed by a second hole on the same prospect. "This is an exciting moment for the company, being the first time in its history that it has launched a major drilling campaign for precious metals, while a recent fund-raising will enable us to expand the programme where appropriate," says Chair Brian Hall.

----------

Macfarlane Group PLC - Glasgow-based packaging firm - Announces acquisition of Carters Packaging Ltd in Cornwall. Carters is a distributor of protective packaging in the south-west of England. The acquisition will go for a maximum cash consideration of GBP4.5 million.

----------

1Spatial PLC - Cambridge-based location data software provider - Announces a multiyear contract with Defra to provide a managed service for Rural Payments Agency's Customer Portal and Land Management System. The total potential contract value over five years for 1Spatial is in excess of GBP900,000. The first three years will net the company GBP600,000, or GBP200,000 a year, while Defra has an option to extend for a further two years for GBP300,000.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
28 Apr 2022 12:52

IN BRIEF: Syncona invests GBP15 million more in OMass Therapeutics

Syncona Ltd - London-based investment company - Invests more into OMass Therapeutics, an Oxford University biotechnology spin-out. After the new GBP15 million investment, Syncona now holds a 31% stake worth GBP44 million in the developer of small molecule drugs. The GBP15 million is part of an oversubscribed GBP75.5 million second round of funding for OMass, which now has raised GBP119 million in total.

Read more
28 Apr 2022 08:59

Syncona takes part in oversubscribed funding round for OMass

(Sharecast News) - Syncona committed further funding for rare-disease specialist OMass Therapeutics alongside a syndicate of investors which included a unit of French drug giant Sanofi.

Read more
11 Apr 2022 09:25

Syncona's investee Anaveon receives good trial data

(Alliance News) - Syncona Ltd on Monday noted that its portfolio company Anaveon AG received "encouraging" first clinical data from its ongoing phase I/II study for ANV419.

Read more
11 Apr 2022 07:49

Syncona's Anaveon to present first clinical data from ANV419 study

(Sharecast News) - Healthcare company Syncona said on Monday that its portfolio company, Anaveon AG, a clinical-stage immuno-oncology business, had announced that the first clinical data from the ongoing Phase I/II study of its lead programme, ANV419, would be presented in a poster at the American Association for Cancer Research's annual meeting in New Orleans.

Read more
1 Apr 2022 07:32

Syncona notes portfolio company Freeline annual loss widens in 2021

(Alliance News) - Syncona Ltd said on Friday that portfolio company Freeline Therapeutics Holdings PLC suffered a widened loss last year.

Read more
11 Mar 2022 08:44

Syncona to invest further USD20 million in Freeline Therapeutics

(Alliance News) - Syncona Ltd said on Friday that it agreed to invest USD20.0 million in Freeline Therapeutics Holdings PLC, as part of the investee's USD26.1 million American depositary shares offering.

Read more
18 Feb 2022 10:03

Syncona completes USD1.5 billion sale of Gyroscope to Novartis

(Alliance News) - Syncona Ltd on Friday said it has completed the sale of Gyroscope Therapeutics Holding PLC to Novartis AG.

Read more
10 Feb 2022 07:47

Syncona's Q3 a 'period of significant activity'

(Sharecast News) - Life sciences firm Syncona said on Thursday that the third quarter had been a "period of significant activity", with $674.0m raised by its portfolio and its third successful exit to date.

Read more
8 Feb 2022 20:38

IN BRIEF: Syncona's Freeline says FLT190 drug "well tolerated"

IN BRIEF: Syncona's Freeline says FLT190 drug "well tolerated"

Read more
22 Dec 2021 17:03

LONDON MARKET CLOSE: Omicron hope lifts FTSE despite UK virus surge

LONDON MARKET CLOSE: Omicron hope lifts FTSE despite UK virus surge

Read more
22 Dec 2021 12:21

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

Read more
22 Dec 2021 10:51

TOP NEWS SUMMARY: Novartis agrees to buy UK's Gyroscope Therapeutics

TOP NEWS SUMMARY: Novartis agrees to buy UK's Gyroscope Therapeutics

Read more
22 Dec 2021 09:12

LONDON MARKET OPEN: Stocks mixed; UK economic recovery slows

LONDON MARKET OPEN: Stocks mixed; UK economic recovery slows

Read more
22 Dec 2021 08:50

Novartis buys UK gene therapy firm Gyroscope for up to USD1.5 billion

Novartis buys UK gene therapy firm Gyroscope for up to USD1.5 billion

Read more
22 Dec 2021 07:03

Syncona sells Gyroscope to Novartis for up to $1.5bn

(Sharecast News) - Syncona on Wednesday said it had sold its portfolio company Gyroscope Therapeutics Holdings to Novartis for up to $1.5bn (£1.1bn) on a cash and debt free basis.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.